Abivax (ABVX) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to -$689.4 million.
- Abivax's Enterprise Value fell 14916.01% to -$689.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$689.4 million, marking a year-over-year decrease of 14916.01%. This contributed to the annual value of -$158.0 million for FY2024, which is 4407.05% up from last year.
- As of Q3 2025, Abivax's Enterprise Value stood at -$689.4 million, which was down 14916.01% from -$73.1 million recorded in Q2 2025.
- In the past 5 years, Abivax's Enterprise Value ranged from a high of -$27.5 million in Q4 2022 and a low of -$689.4 million during Q3 2025
- Its 5-year average for Enterprise Value is -$228.0 million, with a median of -$215.8 million in 2024.
- As far as peak fluctuations go, Abivax's Enterprise Value tumbled by 92182.67% in 2023, and later skyrocketed by 7348.78% in 2025.
- Abivax's Enterprise Value (Quarter) stood at -$69.4 million in 2021, then skyrocketed by 60.4% to -$27.5 million in 2022, then crashed by 921.83% to -$281.0 million in 2023, then skyrocketed by 43.77% to -$158.0 million in 2024, then plummeted by 336.38% to -$689.4 million in 2025.
- Its Enterprise Value was -$689.4 million in Q3 2025, compared to -$73.1 million in Q2 2025 and -$155.7 million in Q1 2025.